What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Monday, November 25th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will post earnings of $2.30 per share for the year. HC Wainwright has a “Sell” rating and a $80.00 price objective on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.07 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

Several other brokerages have also issued reports on SRPT. Barclays cut their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Citigroup cut their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Raymond James restated an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Robert W. Baird reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $137.94 on Wednesday. Sarepta Therapeutics has a 52 week low of $78.67 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81. The company’s 50 day moving average price is $122.16 and its 200 day moving average price is $131.43.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after buying an additional 75 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after acquiring an additional 86 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after acquiring an additional 120 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.